IBM SPSS statistical package version 24 was used in data manipulation. Numeric data explored for normality using Kolmogrov-Smirnov test and Shapiro-Wilk test. Categorical data were expressed as numbers and percentages, while numerical data were summarised as medians and interquartile ranges (IQR). Patients were stratified into subgroups according to their clinicopathological and molecular features. Pairwise comparison between subgroups of CRC patients was tested by Chi-Square test for the categorical data, while Mann-Whitney for 2 groups of numerical one, and Kruskal Wallis for more than 2 groups of numerical data. The effect of FP therapy on genes expression over time (3 and 6 months) in certain subgroup of CRC patients was tested by Wilcoxon matched test. After 3 years of follow up, EFS of patients were tested by Kaplan-Meier procedure. EFS was calculated from the date of resection or neoadjuvant therapy to the date of recurrence, progression or death, which occurred first. EFS for patients who neither progressed, relapsed, nor died, was censored at last assessment prior to loss of follow-up. Significant clinicopathological and molecular variables on patients’ survival were tested for their hazardous effects on progression using multivariate COX proportion hazard model. All P-values were two-sided, adjusted for multiple comparisons, and the P-values ⩽.05 were considered significant.

Note: The content above has been extracted from a research article, so it may not display correctly.

Please log in to submit your questions online.
Your question will be posted on the Bio-101 website. We will send your questions to the authors of this protocol and Bio-protocol community members who are experienced with this method. you will be informed using the email address associated with your Bio-protocol account.

We use cookies on this site to enhance your user experience. By using our website, you are agreeing to allow the storage of cookies on your computer.